Gujarat Themis Biosyn Allots ₹585 Crore NCDs for Japan Subsidiary Acquisition
Gujarat Themis Biosyn Limited has allotted ₹585 Crore in Non-Convertible Debentures (NCDs) via private placement on September 16, 2026. The funds will finance the acquisition of MicroBiopharm Japan Co., Ltd. and general corporate purposes. The NCDs are secured and have tenures of 60 and 18 months.
The fundraising of ₹585 Crores and its allocation towards a subsidiary acquisition is a material event that can significantly impact the company's growth and financial structure.
The company has successfully raised significant capital through NCDs, which will be used for a strategic acquisition and general corporate purposes, indicating positive business development.
Gujarat Themis Biosyn Limited announced the allotment of Non-Convertible Debentures (NCDs) aggregating ₹585 Crores on a private placement basis. This decision was made by the Committee of the Board of Directors during their meeting held on September 16, 2026.
The proceeds from these NCDs will be utilized for investing in the company's wholly-owned subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd. Additionally, a portion of the funds will be used for general corporate purposes.
The NCDs are secured, redeemable, unlisted, and rated. They comprise two series: NCD Series 1, aggregating ₹295 Crores with a tenure of 60 months from the effective date, and NCD Series 2, aggregating ₹290 Crores with a tenure of 18 months from the effective date. Both series carry an interest rate of 10% p.a. compounded monthly for Series 1 and 17.75% p.a. compounded monthly for Series 2, with coupons payable quarterly. The issuance is not proposed to be listed on any stock exchange.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.